Blog

20 Articles

Kim Reiss Binder
Research
November 1, 2018 • 5 Min

PARP Inhibitors for Pancreatic Cancer Maintenance Treatment

Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.

DNA representation
Research
December 5, 2017 • 5 Min

The ABCs of Genetic Testing

There are a number of different genetic mutations that can cause familial pancreatic cancer. This article explains some of the most common ones.

Gloria Peterson, Ph.D.
Research
October 12, 2017 • 5 Min

Tumor Genetics Research Brings Some Answers for Families at High Risk

Professor Gloria Peterson of the Mayo Clinic is working on tumor genetics to help make early detection of pancreatic cancer a reality.

Illustration of a protein that includes the BRCA2 mutation. The illustration includes spirals in brown, strands in purple, blue directional arrows, and green, yellow, red, and blue circles.
Research
June 27, 2017 • 2 Min

A Maintenance Trial for Patients with BRCA or PALB2 Mutations

A clinical trial examines whether the PARP inhibitor rucaparib can work as a maintenance drug for pancreatic cancer patients with BRCA or PALB2 mutations.

Microscopy image of a tumor section (obtained from a mouse tumor model) shows the blue-stained nanoparticles selectively accumulating in the peripheral tumor area and then penetrating into tumor cells
Research
August 18, 2016 • 2 Min

Exploring the Effectiveness of an Experimental Class of Drug

Does adding a PARP inhibitor drug to standard treatment help control the spread of advanced pancreatic cancer in patients with the BRCA mutation?

  • 1
  • 2